3月28日周五盘中，港股上市公司翰森制药（03692.HK）股价大涨5.19%，引发市场关注。这一涨势似乎与近期港股医药板块整体走强有关。
近期，多家港股创新药企公布了2024年财报，业绩普遍向好。例如，信达生物（01801.HK）在非国际财务报告准则下首次实现盈利；三生制药（01530.HK）净利润同比增长34.9%；中国生物制药（01177.HK）净利润同比增长33.5%。这些利好消息激发了投资者对医药板块的信心，带动整个行业股价上涨。
虽然翰森制药尚未公布最新财报，但作为医药板块的重要成员，公司股价似乎也受到了行业整体向好的带动。此外，即将于4月底举行的2025年美国癌症研究协会（AACR）年会也可能成为短期内推动医药股走强的催化剂。分析人士认为，随着创新药企进入商业化密集收获期，加上政策支持和人口老龄化等因素，港股医药板块有望继续保持增长势头。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.